From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

The trials of John Story – is he the forced seller at Asimilar?

By Tom Winnifrith, The Sheriff of AIM | Friday 30 April 2021


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


The shock suspension of All Active Asset (AAA), the plaything of foul-mouthed troll and penny share huckster Chris Akers, was especially painful for one shareholder – the proven liar John Story as he faced big margin calls in the fraud Zoetic (ZOE). How to meet those margin calls? Well I have established that he is on a lock-in at Cellular Goods (CBX) with his 15 million shares. Has he stuck to that lock-in? Enquiries continue. If he has sold even one share then he needs to issue a TR1 as he is on 3% and that would be a bit embarrassing given the lock-in.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 17:43:07